Molecular Pathophysiology of Myelodysplastic Syndromes

Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1

Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836 · see citing works

Alternative isoform regulation in human tissue transcriptomes

Wang, E. T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., Kingsmore, S. F., Schroth, G. P., & Burge, C. B. (2008) · Nature · doi:10.1038/nature07509 · Cited by 5,181 · see citing works

International scoring system for evaluating prognosis in myelodysplastic syndromes

Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · see citing works

Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing

Pan, Q., Shai, O., Lee, L. J., Frey, B. J., & Blencowe, B. J. (2008) · Nature Genetics · doi:10.1038/ng.259 · Cited by 3,951 · see citing works

Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine

Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451 · see citing works

WHO Classification: Tumours of the Haematopoietic and Lymphoid Tissues (2008)

(2015) · doi:10.1002/9781118853771.ch51 · Cited by 3,290 · see citing works

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · see citing works

Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA

He, Y., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. (2011) · Science · doi:10.1126/science.1210944 · Cited by 2,776 · see citing works

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · see citing works

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · see citing works

Genome-scale DNA methylation maps of pluripotent and differentiated cells

Meissner, A., Mikkelsen, T. S., Gu, H., Wernig, M., Hanna, J., Sivachenko, A., Zhang, X., Bernstein, B. E., Nusbaum, C., Jaffe, D. B., et al. (2008) · Nature · doi:10.1038/nature07107 · Cited by 2,536 · see citing works

Recurring mutations found by sequencing an acute myeloid leukemia genome

Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219 · see citing works

Frequent pathway mutations of splicing machinery in myelodysplasia

Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029 · see citing works

<i>DNMT3A</i> Mutations in Acute Myeloid Leukemia

Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983 · see citing works

Spliceosome Structure and Function

Will, C. L., & Luhrmann, R. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003707 · Cited by 1,829 · see citing works

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D. A., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,814 · see citing works

Mutation in <i>TET2</i> in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · see citing works

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,670 · see citing works

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627 · see citing works

Myelodysplastic Syndromes

Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., Castro, C. M. D., Deeg, H. J., Frankfurt, O., Gaensler, K. M. L., Garcia-Manero, G., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0104 · Cited by 1,623 · see citing works

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339 · see citing works

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · see citing works

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R. D., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,294 · see citing works

Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts

Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222 · see citing works

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · see citing works

Dnmt3a is essential for hematopoietic stem cell differentiation

Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.1009 · Cited by 1,122 · see citing works

Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells

Ball, M. P., Li, J. B., Gao, Y., Lee, J., LeProust, E. M., Park, I., Xie, B., Daley, G. Q., & Church, G. M. (2009) · Nature Biotechnology · doi:10.1038/nbt.1533 · Cited by 1,087 · see citing works

Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis

Novershtern, N., Subramanian, A., Lawton, L. N., Mak, R. H., Haining, W. N., McConkey, M. E., Habib, N., Yosef, N., Chang, C. Y., Shay, T., et al. (2011) · Cell · doi:10.1016/j.cell.2011.01.004 · Cited by 942 · see citing works

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

Ebert, B. L., Pretz, J. L., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E. C., Ellis, S. R., et al. (2008) · Nature · doi:10.1038/nature06494 · Cited by 925 · see citing works

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924 · see citing works

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhingedPreprint

David, C. J., & Manley, J. L. (2010) · Genes & Development · doi:10.1101/gad.1973010 · Cited by 815 · see citing works

Ribosomopathies: human disorders of ribosome dysfunction

Narla, A., & Ebert, B. L. (2010) · Blood · doi:10.1182/blood-2009-10-178129 · Cited by 806 · see citing works

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

Yan, X., Xu, J., Gu, Z., Pan, C., Lü, G., Shen, Y., Shi, J., Zhu, Y., Tang, L., Zhang, X., et al. (2011) · Nature Genetics · doi:10.1038/ng.788 · Cited by 806 · see citing works

IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication

Paschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Käyser, S., Zucknick, M., Götze, K. S. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 803 · see citing works

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

Haase, D. T., Germing, U., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kündgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A. A. N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-082404 · Cited by 792 · see citing works

Acquired mutations in TET2 are common in myelodysplastic syndromes

Langemeijer, S. M. C., Kuiper, R. P., Berends, M., Knops, R., Aslanyan, M. G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A. G., Raymakers, R. A. P., et al. (2009) · Nature Genetics · doi:10.1038/ng.391 · Cited by 755 · see citing works

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

Nikoloski, G., Langemeijer, S. M. C., Kuiper, R. P., Knops, R., Massop, M., Tönnissen, E., van der Heijden, A., Scheele, T. N., Vandenberghe, P., de Witte, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.620 · Cited by 754 · see citing works

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727 · see citing works

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

Schanz, J., Tüchler, H., Solé, F. G., Mallo, M., Luño, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6394 · Cited by 688 · see citing works

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies

Li, Z., Cai, X., Cai, C.-L., Wang, J., Zhang, W., Petersen, B. E., Yang, F.-C., & Xu, M. (2011) · Blood · doi:10.1182/blood-2010-12-325241 · Cited by 671 · see citing works

Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype

Starczynowski, D. T., Kuchenbauer, F. C., Argiropoulos, B., Sung, S., Morin, R. D., Muranyi, A., Hirst, M., Hogge, D. E., Marra, M. A., Wells, R. A., et al. (2009) · Nature Medicine · doi:10.1038/nm.2054 · Cited by 655 · see citing works

Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice

Ko, M., Bandukwala, H. S., An, J., Lamperti, E. D., Thompson, E. C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S. B., & Rao, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112317108 · Cited by 616 · see citing works

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation

Yap, D., Chu, J., Berg, T., Schapira, M., Cheng, S., Moradian, A., Morin, R. D., Mungall, A. J. J., Meissner, B., Boyle, M., et al. (2010) · Blood · doi:10.1182/blood-2010-11-321208 · Cited by 609 · see citing works

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 592 · see citing works

Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cellsPreprint

Wu, H., D’Alessio, A. C., Ito, S., Wang, Z., 崔凯荣, Zhao, K., Sun, Y. E., & Zhang, Y. (2011) · Genes & Development · doi:10.1101/gad.2036011 · Cited by 585 · see citing works

Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

Graubert, T. A., Shen, D., Ding, L., Okeyo-Owuor, T., Shirai, C. L., Shao, J., Krysiak, K., Harris, C. C., Koboldt, D. C., Larson, D. E., et al. (2011) · Nature Genetics · doi:10.1038/ng.1031 · Cited by 582 · see citing works

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

Walter, M. J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.44 · Cited by 527 · see citing works

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Malcovati, L., Papaemmanuil, E., Bowen, D., Boultwood, J., Porta, M. G. D., Pascutto, C., Travaglino, E., Groves, M. J., Godfrey, A. L., Ambaglio, I., et al. (2011) · Blood · doi:10.1182/blood-2011-09-377275 · Cited by 496 · see citing works

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Fenaux, P., Giagounidis, A. A. N., Selleslag, D., Beyne‐Rauzy, O., Mufti, G. J., Mittelman, M., Muus, P., Boekhorst, P. A. W. T., Sanz, G. F., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 488 · see citing works

Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas

Furukawa, T., Kuboki, Y., Tanji, E., Yoshida, S., Hatori, T., Yamamoto, M., Shibata, N., Shimizu, K., Kamatani, N., & Shiratori, K. (2011) · Scientific Reports · doi:10.1038/srep00161 · Cited by 442 · see citing works

Distinct haematological disorder with deletion of long arm of No. 5 chromosome

BERGHE, H. V. D., Cassiman, J., David, G., Fryns, J., Michaux, J., & SOKAL, G. (1974) · Nature · doi:10.1038/251437a0 · Cited by 442 · see citing works

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

Bejar, R. L., Stevenson, K. E., Caughey, B. A., Abdel-Wahab, O. I., Steensma, D. P., Galili, N., Raza, A., Kantarjian, H. M., Levine, R. L., Neuberg, D. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7379 · Cited by 442 · see citing works

High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia

Romana, S., Poirel, H., Leconiat, M., Flexor, M., Mauchauffe, M., Jonveaux, P., Macintyre, E., Berger, R., & Bernard, O. (1995) · Blood · doi:10.1182/blood.v86.11.4263.bloodjournal86114263 · Cited by 427 · see citing works

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells

Dutt, S., Narla, A., Lin, K. I., Mullally, A., Abayasekara, N., Megerdichian, C., Wilson, F. H., Currie, T., Khanna‐Gupta, A., Berliner, N., et al. (2010) · Blood · doi:10.1182/blood-2010-07-295238 · Cited by 410 · see citing works

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

Sanada, M., Suzuki, T., Shih, L., Otsu, M., Kato, M., Yamazaki, S., Tamura, A., Honda, H., Sakata‐Yanagimoto, M., Kumano, K., et al. (2009) · Nature · doi:10.1038/nature08240 · Cited by 401 · see citing works

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

Jiang, Y., Dunbar, A., Gondek, L. P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2008-06-163246 · Cited by 384 · see citing works

Silencing chromatin: comparing modes and mechanisms

Beisel, C., & Paro, R. (2011) · Nature reviews genetics · doi:10.1038/nrg2932 · Cited by 378 · see citing works

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

Shen, L.-L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S. S., Zhu, W., Pierce, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4781 · Cited by 348 · see citing works

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome

Barlow, J. L., Drynan, L. F., Hewett, D. R., Holmes, L. R., Lorenzo-Abalde, S., Lane, A. L., Jolin, H. E., Pannell, R., Middleton, A. J., Wong, S. H., et al. (2009) · Nature Medicine · doi:10.1038/nm.2063 · Cited by 337 · see citing works

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

Figueroa, M. E., Skrabanek, L. A., Li, Y., Jiemjit, A., Fandy, T. E., Paietta, E. M., Fernandez, H. F., Tallman, M. S., Greally, J. M., Carraway, H. E., et al. (2009) · Blood · doi:10.1182/blood-2009-01-200519 · Cited by 325 · see citing works

TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Metzeler, K. H., Maharry, K. S., Radmacher, M. D., Mrózek, K., Margeson, D., Becker, H., Curfman, J. P., Holland, K. B., Schwind, S., Whitman, S. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7742 · Cited by 316 · see citing works

Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML

Gondek, L. P., Tiu, R. V., O’Keefe, C. L., Sekeres, M. A., Theil, K. S., & Maciejewski, J. P. (2007) · Blood · doi:10.1182/blood-2007-05-092304 · Cited by 315 · see citing works

Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor Prognosis

Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308 · see citing works

Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes

Bejar, R. L., Levine, R. L., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 303 · see citing works

250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl , in Myeloid Malignancies

Dunbar, A. J., Gondek, L. P., O’Keefe, C. L., Makishima, H., Rataul, M. S., Szpurka, H., Sekeres, M. A., Wang, X., McDevitt, M. A., & Maciejewski, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2754 · Cited by 300 · see citing works

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1

Kohlmann, A., Großmann, V., Klein, H., Schindela, S., Weiss, T., Kazak, B., Dicker, F., Schnittger, S., Dugas, M., Kern, W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1361 · Cited by 300 · see citing works

Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survivalPreprint

Hock, H. R., Meade, E., Medeiros, S., Schindler, J. W., Valk, P. J. M., Fujiwara, Y., & Orkin, S. H. (2004) · Genes & Development · doi:10.1101/gad.1239604 · Cited by 295 · see citing works

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia

Loh, M. L., Sakai, D. S., Flotho, C., Kang, M. W., Fliegauf, M., Archambeault, S., Mullighan, C. G., Chen, L., Bergsträßer, E., Bueso-Ramos, C., et al. (2009) · Blood · doi:10.1182/blood-2009-01-198416 · Cited by 287 · see citing works

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia

Harada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A., & Inaba, T. (2004) · Blood · doi:10.1182/blood-2003-09-3074 · Cited by 281 · see citing works

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)

Kosmider, O., Gelsi‐Boyer, V., Cheok, M. H.-C., Grabar, S., Della-Valle, V., Picard, F., Viguié, F., Quesnel, B., Beyne‐Rauzy, O., Solary, É., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215814 · Cited by 276 · see citing works

Prognostic Significance ofASXL1Mutations in Patients With Myelodysplastic Syndromes

Thol, F. R., Friesen, I., Damm, F., Yun, H., Weissinger, E. M., Krauter, J., Wagner, K., Chaturvedi, A., Sharma, A., Wichmann, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4938 · Cited by 276 · see citing works

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

Metzeler, K. H., Becker, H., Maharry, K. S., Radmacher, M. D., Kohlschmidt, J., Mrózek, K., Nicolet, D., Whitman, S. P., Wu, Y.-Z., Schwind, S., et al. (2011) · Blood · doi:10.1182/blood-2011-08-368225 · Cited by 275 · see citing works

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia

Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M. J., Larrayoz, M. J., Garcia-Delgado, M., Giagounidis, A., Malcovati, L., et al. (2010) · Leukemia · doi:10.1038/leu.2010.20 · Cited by 264 · see citing works

Narrowing and genomic annotation of the commonly deleted region of the 5q− syndrome

Boultwood, J., Fidler, C., Strickson, A., Watkins, F., Gama, S., Kearney, L., Tosi, S., Kasprzyk, A., Cheng, J., Jaju, R. J., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4638 · Cited by 264 · see citing works

Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission

Tehranchi, R., Woll, P. S., Anderson, K., Buza-Vidas, N., Mizukami, T., Mead, A. J., Åstrand‐Grundström, I., Strömbeck, B., Horvat, A., Ferry, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912228 · Cited by 253 · see citing works

Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases.

Beau, M. M. L., Espinosa, R., Davis, E. M., Eisenbart, J. D., Larson, R. A., & Green, E. D. (1996) · PubMed · doi:10.1182/blood.v88.6.1930.bloodjournal8861930 · Cited by 232 · see citing works

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value

Smith, A., Mohamedali, A. M., Kulasekararaj, A. G., Lim, Z., Gäken, J. A., Lea, N. C., Przychodzen, B. P., Mian, S. A., Nasser, E. E., Shooter, C. C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-274704 · Cited by 224 · see citing works

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia

Gelsi‐Boyer, V., Trouplin, V., Roquain, J., Adélaı̈de, J., Carbuccia, N., Esterni, B., Finetti, P., Murati, A., Arnoulet, C., Zerazhi, H., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08381.x · Cited by 222 · see citing works

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value

Patnaik, M. M., Lasho, T. L., Hodnefield, J. M., Knudson, R. A., Ketterling, R. P., Garcia‐Manero, G., Steensma, D. P., Pardanani, A. D., Hanson, C. A., & Tefferi, A. (2011) · Blood · doi:10.1182/blood-2011-09-377994 · Cited by 201 · see citing works

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

Thol, F. R., Weissinger, E. M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Göhring, G., Schumann, C., Bug, G., Ottmann, O. G., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.025494 · Cited by 193 · see citing works

Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production

Ward, P. S., Cross, J. R., Lü, C., Weigert, O., Abdel-Wahab, O. I., Levine, R. L., Weinstock, D. M., Sharp, K. A., & Thompson, C. B. (2011) · Oncogene · doi:10.1038/onc.2011.416 · Cited by 191 · see citing works

EVI1 induces myelodysplastic syndrome in mice

Buonamici, S., Li, D., Chi, Y., Zhao, R., Wang, X., Brace, L. D., Ni, H., Saunthararajah, Y., & Nucifora, G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21716 · Cited by 181 · see citing works

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

Makishima, H., Jankowska, A. M., Tiu, R. V., Szpurka, H., Sugimoto, Y., Hu, Z., Saunthararajah, Y., Guinta, K., Keddache, M. A., Putnam, P., et al. (2010) · Leukemia · doi:10.1038/leu.2010.167 · Cited by 179 · see citing works

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

Score, J., Hidalgo-Curtis, C., Jones, A. V., Winkelmann, N., Skinner, A., Ward, D., Zoi, K., Ernst, T., Stegelmann, F., Döhner, K., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367243 · Cited by 177 · see citing works

Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome

Sloand, E. M., Mainwaring, L. A., Führer, M., Ramkissoon, S. H., Risitano, A. M., Keyvanafar, K., Lu, J., Basu, A., Barrett, A. J., & Young, N. S. (2005) · Blood · doi:10.1182/blood-2004-05-2017 · Cited by 175 · see citing works

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder

Preudhomme, C., Renneville, A., Bourdon, V., Philippe, N., Roche‐Lestienne, C., Boissel, N., Dhédin, N., André, J.-M., Cornillet‐Lefèbvre, P., Baruchel, A., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168260 · Cited by 173 · see citing works

Myelodysplastic Syndromes/Neoplasms—Overview

Naeim, F., Rao, P. N., Song, S. X., & Grody, W. W. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385183-3.00008-5 · Cited by 166 · see citing works

Involvement and functional impairment of the CD34+CD38−Thy-1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8

Nilsson, L., Åstrand‐Grundström, I., Anderson, K., Arvidsson, I., Hokland, P., Bryder, D., Kjeldsen, L., Johansson, B., Hellström-Lindberg, E., Hast, R., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0188 · Cited by 163 · see citing works

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System

Schanz, J., Steidl, C., Fonatsch, C., Pfeilstöcker, M., Nösslinger, T., Tuechler, H., Valent, P., Hildebrandt, B., Giagounidis, A. A. N., Aul, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3978 · Cited by 159 · see citing works

Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia

Fisher, C. L., Pineault, N., Brookes, C., Helgason, C. D., Ohta, H., Bodner, C., Hess, J. L., Humphries, R. K., & Brock, H. W. (2009) · Blood · doi:10.1182/blood-2009-07-230698 · Cited by 154 · see citing works

A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia

Bacher, U., Haferlach, T., Kern, W., Haferlach, C., & Schnittger, S. (2007) · Haematologica · doi:10.3324/haematol.10869 · Cited by 152 · see citing works

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

Adès, L., Boehrer, S., Prébet, T., Beyne‐Rauzy, O., Legros, L., Ravoet, C., Dreyfus, F., Stamatoullas, A., Chaury, M., Delaunay, J., et al. (2008) · Blood · doi:10.1182/blood-2008-08-175778 · Cited by 151 · see citing works

Gene expression profiling of CD34+ cells in patients with the 5q− syndrome

Boultwood, J., Pellagatti, A., Cattan, H., Lawrie, C. H., Giagounidis, A. A. N., Malcovati, L., Porta, M. G. D., Jädersten, M., Killick, S. B., Fidler, C., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06833.x · Cited by 151 · see citing works

AML1 mutations induced MDS and MDS/AML in a mouse BMT model

Watanabe‐Okochi, N., Kitaura, J., Ono, R., Harada, H., Harada, Y., Komeno, Y., Nakajima, H., Nosaka, T., Inaba, T., & Kitamura, T. (2008) · Blood · doi:10.1182/blood-2007-01-068346 · Cited by 151 · see citing works

DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms

Abdel-Wahab, O. I., Pardanani, A. D., Rampal, R. K., Lasho, T. L., Levine, R. L., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.82 · Cited by 151 · see citing works

Chronic myelomonocytic leukemia

Bennett, J. M. (2002) · Current Treatment Options in Oncology · doi:10.1007/s11864-002-0011-6 · Cited by 146 · see citing works

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

Malcovati, L., Porta, M. G. D., Pietra, D., Boveri, E., Pellagatti, A., Gallì, A., Travaglino, E., Brisci, A., Rumi, E., Passamonti, F., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222331 · Cited by 144 · see citing works

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients

Patnaik, M. M., Hanson, C. A., Hodnefield, J. M., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.298 · Cited by 144 · see citing works

TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance

PELLER, S., & Rotter, V. (2003) · Human Mutation · doi:10.1002/humu.10190 · Cited by 141 · see citing works

Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation

Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2004) · Blood · doi:10.1182/blood-2004-02-0754 · Cited by 135 · see citing works

RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome

Chen, C., Lin, L., Tang, J., Ko, B.-S., Tsay, W., Chou, W., Yao, M., Wu, S., Tseng, M., & Tien, H. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06811.x · Cited by 134 · see citing works

Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse

Sportoletti, P., Grisendi, S., Majid, S. M., Cheng, K., Clohessy, J. G., Viale, A. J., Teruya‐Feldstein, J., & Pandolfi, P. P. (2008) · Blood · doi:10.1182/blood-2007-06-098251 · Cited by 133 · see citing works

Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia

Christiansen, D. H., Andersen, M. K., Desta, F. Z., & Pedersen-Bjergaard, J. (2005) · Leukemia · doi:10.1038/sj.leu.2404009 · Cited by 121 · see citing works

Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant‐negative, or hypomorphic alleles

Matheny, C., Speck, M. E., Cushing, P. R., Zhou, Y., Corpora, T., Regan, M. C., Newman, M. N., Roudaia, L., Speck, C. L., Gu, T.-L., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601568 · Cited by 120 · see citing works

CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes

Reindl, C., Quentmeier, H., Petropoulos, K., Greif, P. A., Benthaus, T., Argiropoulos, B., Mellert, G., Vempati, S., Duyster, J., Buske, C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1325 · Cited by 120 · see citing works

TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia.

Schindler, J. W., Vanburen, D. G., Foudi, A., Krejčí, O., Qin, J.-Z., Orkin, S., & Hock, H. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.04.019 · Cited by 116 · see citing works

Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2

Ho, C. Y., Otterud, B., Legare, R. D., Varvil, T., Saxena, R., Dehart, D. B., Kohler, S., Aster, J. C., Dowton, S. B., Li, F., et al. (1996) · Blood · doi:10.1182/blood.v87.12.5218.bloodjournal87125218 · Cited by 110 · see citing works

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q− syndrome

Kumar, M. S., Narla, A., Nonami, A., Mullally, A., Dimitrova, N., Ball, B. J., McAuley, J. R., Poveromo, L., Kutok, J. L., Galili, N., et al. (2011) · Blood · doi:10.1182/blood-2010-12-324715 · Cited by 110 · see citing works

Mammalian Polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1Preprint

Isono, K., Mizutani-Koseki, Y., Komori, T., Schmidt-Zachmann, M. S., & Koseki, H. (2005) · Genes & Development · doi:10.1101/gad.1284605 · Cited by 110 · see citing works

Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited

Jerez, A., Gondek, L. P., Jankowska, A. M., Makishima, H., Przychodzen, B. P., Tiu, R. V., O’Keefe, C. L., Mohamedali, A. M., Batista, D., Sekeres, M. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1824 · Cited by 110 · see citing works

TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities

Kaneko, H., Misawa, S., Horiike, S., Nakai, H., & Kashima, K. (1995) · Blood · doi:10.1182/blood.v85.8.2189.bloodjournal8582189 · Cited by 101 · see citing works

CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins

Sloand, E. M., Pfannes, L. V., Chen, G., Shah, S., Solomou, E. E., Barrett, J. A., & Young, N. S. (2006) · Blood · doi:10.1182/blood-2006-01-030643 · Cited by 101 · see citing works

Loss of Mll5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation

Heuser, M., Yap, D., Leung, M., de Algara, T. R., Tafech, A., McKinney, S. E., Dixon, J., Thresher, R. R., Colledge, B., Carlton, M. B. L., et al. (2008) · Blood · doi:10.1182/blood-2008-06-162263 · Cited by 101 · see citing works

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

Jädersten, M., Saft, L., Pellagatti, A., Göhring, G., Wainscoat, J. S., Boultwood, J., Porwit‐MacDonald, A., Schlegelberger, B., & Hellström‐Lindberg, E. (2009) · Haematologica · doi:10.3324/haematol.2009.011528 · Cited by 100 · see citing works

The Apcmin mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS

Lane, S., Sykes, S. M., Al‐Shahrour, F., Shterental, S., Paktinat, M., Celso, C. L., Jesneck, J. L., Ebert, B. L., Williams, D. A., & Gilliland, D. G. (2010) · Blood · doi:10.1182/blood-2009-11-251728 · Cited by 99 · see citing works

EVI1 and hematopoietic disorders: History and perspectives

Nucifora, G., Laricchia‐Robbio, L., & Senyuk, V. I. (2005) · Gene · doi:10.1016/j.gene.2005.09.020 · Cited by 95 · see citing works

FLT3 and NPM1 Mutations in Myelodysplastic Syndromes

Bains, A., Luthra, R., Medeiros, L. J., & Zuo, Z. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpei9xu8pybcio · Cited by 95 · see citing works

Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes

Germing, U., Strupp, C., Giagounidis, A. A. N., Haas, R. R., Gattermann, N., Starke, C., & Aul, C. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.02.014 · Cited by 90 · see citing works

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics

Heinrichs, S., Kulkarni, R. V., Bueso‐Ramos, C. E., Levine, R. L., Loh, M. L., Li, C., Neuberg, D. S., Kornblau, S. M., Issa, J. J., Gilliland, D. G., et al. (2009) · Leukemia · doi:10.1038/leu.2009.82 · Cited by 89 · see citing works

International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome

Kita‐Sasai, Y., Horiike, S., Misawa, S., Kaneko, H., Kobayashi, M., Nakao, M., Nakagawa, H., Fujii, H., & Taniwaki, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03073.x · Cited by 88 · see citing works

Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice

Fisher, C. L., Lee, I., Bloyer, S., Bozza, S., Chevalier, J. R., Dahl, A., Bodner, C., Helgason, C. D., Hess, J. L., Humphries, R. K., et al. (2009) · Developmental Biology · doi:10.1016/j.ydbio.2009.10.004 · Cited by 86 · see citing works

T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy

Sloand, E. M., Melenhorst, J. J., Tucker, Z. C. G., Pfannes, L. V., Brenchley, J. M., Yong, A. S. M., Visconte, V., Wu, C. O., Emma Gostick, D., Scheinberg, P., et al. (2010) · Blood · doi:10.1182/blood-2010-04-277921 · Cited by 81 · see citing works

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

Damm, F., Thol, F. R., Kosmider, O., Kade, S., Löffeld, P., Dreyfus, F., Stamatoullas, A., Schmidt, A., Beyne‐Rauzy, O., de Botton, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.321 · Cited by 81 · see citing works

The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations

Huang, G., Zhao, X., Wang, L., Elf, S., Xu, H., Zhao, X., Sashida, G., Zhang, Y., Liu, Y., Lee, J., et al. (2011) · Blood · doi:10.1182/blood-2010-11-317909 · Cited by 79 · see citing works

Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype

Akagi, T., Ogawa, S., Dugas, M., Kawamata, N., Yamamoto, G., Nannya, Y., Sanada, M., Miller, C. W., Yung, A., Schnittger, S., et al. (2009) · Haematologica · doi:10.3324/haematol.13024 · Cited by 77 · see citing works

Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild‐type TP53

Kanagal‐Shamanna, R., Bueso-Ramos, C., Barkoh, B. A., Lu, G. G., Wang, S., Garcia‐Manero, G., Vadhan‐Raj, S., Hoehn, D., Medeiros, L. J., & Yin, C. C. (2011) · Cancer · doi:10.1002/cncr.26537 · Cited by 76 · see citing works

Rare occurrence of DNMT3A mutations in myelodysplastic syndromes

Thol, F. R., Winschel, C., Lüdeking, A., Yun, H., Friesen, I., Damm, F., Wagner, K., Krauter, J., Heuser, M., & Ganser, A. (2011) · Haematologica · doi:10.3324/haematol.2011.045559 · Cited by 74 · see citing works

Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia

van Doorn-Khosrovani, S. B. V. W., Spensberger, D., de Knegt, Y., Tang, M., Löwenberg, B., & Delwel, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208588 · Cited by 73 · see citing works

Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.

Niimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T., & Kimura, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404136 · Cited by 69 · see citing works

Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course

McClure, R. F., Dewald, G., Hoyer, J. D., & Hanson, C. A. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01537.x · Cited by 68 · see citing works

FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation

Vu, H. A., Xinh, P. T., Masuda, M., Motoji, T., Toyoda, A., Sakaki, Y., Tokunaga, K., & Sato, Y. (2006) · Leukemia · doi:10.1038/sj.leu.2404266 · Cited by 68 · see citing works

Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

Loh, M. L., Martinelli, S., Cordeddu, V., Reynolds, M. G., Vattikuti, S., Lee, C. M., Wulfert, M., Germing, U., Haas, P. S., Niemeyer, C. M., et al. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.10.001 · Cited by 66 · see citing works

Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement?

Viguié, F., Aboura, A., Bouscary, D., Ramond, S., Delmer, A. J., Tachdjian, G., Marie, J., & Casadevall, N. (2005) · Leukemia · doi:10.1038/sj.leu.2403818 · Cited by 66 · see citing works

Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome

McGowan, K. A., Pang, W. W., Bhardwaj, R., Perez, M. G., Pluvinage, J. V., Glader, B. E., Malek, R. A., Mendrysa, S. M., Weissman, I. L., Park, C. Y., et al. (2011) · Blood · doi:10.1182/blood-2010-11-318584 · Cited by 63 · see citing works

Correlation of cytogenetic, molecular cytogenetic, and clinical findings in 59 patients with ANLL or MDS and abnormalities of the short arm of chromosome 12

Streubel, B., Sauerland, C., Heil, G., Freund, M., Bartels, H., Lengfelder, E., Wandt, H., Ludwig, W., Nowotny, H., Baldus, M., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00591.x · Cited by 61 · see citing works

Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia

Bacher, U., Haferlach, T., Schnittger, S., Kreipe, H. H., & Kröger, N. M. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08631.x · Cited by 60 · see citing works

ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events

Haferlach, C., Bacher, U., Schnittger, S., Alpermann, T., Zenger, M., Kern, W., & Haferlach, T. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21918 · Cited by 59 · see citing works

Somatic point mutations in RUNX1/CBFA2/AML1 are common in high‐risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia

Steensma, D. P., Gibbons, R. J., Mesa, R. A., Tefferi, A., & Higgs, D. R. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00363.x · Cited by 58 · see citing works

Myelodysplastic Syndromes

Orazi, A., & Czader, M. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcprcxx4r0yhkwv · Cited by 52 · see citing works

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

Möllgård, L., Saft, L., Treppendahl, M. B., Dybedal, I., Nørgaard, J. M., Astermark, J., Ejerblad, E., Garelius, H. G., Dufva, I. H., Jansson, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.039669 · Cited by 51 · see citing works

Integrated Genomic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelodysplastic Syndromes Pathogenesis

Graubert, T. A., Payton, M. A., Shao, J., Walgren, R. A., Monahan, R. S., Frater, J. L., Walshauser, M. A., Martin, M. G., Kasai, Y., & Walter, M. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004583 · Cited by 50 · see citing works

A critical role for SHP2 in STAT5 activation and growth factor–mediated proliferation, survival, and differentiation of human CD34+ cells

Li, L., Modi, H., McDonald, T., Rossi, J., Yee, J., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-06-288910 · Cited by 49 · see citing works

C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells

Satoh, Y., Matsumura, I., Tanaka, H., Harada, H., Harada, Y., Matsui, K., Shibata, M., Mizuki, M., & Kanakura, Y. (2011) · Leukemia · doi:10.1038/leu.2011.202 · Cited by 47 · see citing works

Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells

MacGrogan, D., Kalakonda, N., Álvarez, S., Scandura, J. M., Boccuni, P., Johansson, B., & Nimer, S. D. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20087 · Cited by 45 · see citing works

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities

Kantarjian, H. M., O'Brien, S. M., Ravandi, F., Borthakur, G. M., Faderl, S. H., Bueso-Ramos, C., Abruzzo, L. V., Pierce, S. A., Shan, J., Issa, J. J., et al. (2009) · Cancer · doi:10.1002/cncr.24575 · Cited by 44 · see citing works

Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears

Kamp, H. V., de Pijper, C., Vries, M. V., Bos, J. L., Leeksma, C. H. W., Kerkhofs, H., Willemze, R., Fibbe, W., & Landegent, J. E. (1992) · Blood · doi:10.1182/blood.v79.5.1266.1266 · Cited by 40 · see citing works

Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies

Wong, J. C. Y., Zhang, Y., Lieuw, K. H., Tran, M. T., Forgó, E., Weinfurtner, K. M., Alzamora, P., Kogan, S. C., Akagi, K., Wolff, L., et al. (2010) · Blood · doi:10.1182/blood-2009-07-232504 · Cited by 26 · see citing works

Myelodysplastic Syndromes (MDS)

Pleyer, L., Neureiter, D., Faber, V., & Greil, R. (2010) · Springer eBooks · doi:10.1007/978-3-211-79892-8_6 · Cited by 24 · see citing works

Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value

Constantinidou, M., Chalevelakis, G., Economopoulos, T., Koffa, M. D., Liloglou, T., Anastassiou, C., Yalouris, A., Spandidos, D. A., & Raptis, S. A. (1997) · Annals of Hematology · doi:10.1007/s002770050248 · Cited by 23 · see citing works

ETV6 and PDGFRB: a license to fuse

Lierman, E., & Cools, J. (2007) · Haematologica · doi:10.3324/haematol.11187 · Cited by 21 · see citing works

Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells

Maratheftis, C. I., Bolaraki, P. E., Giannouli, S., Kapsogeorgou, E. K., Moutsopoulos, H. Μ., & Voulgarelis, M. (2006) · Leukemia Research · doi:10.1016/j.leukres.2005.12.021 · Cited by 19 · see citing works

Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes

Caudill, J. S. C., Porcher, J. C., & Steensma, D. P. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190801971690 · Cited by 14 · see citing works

Ras mutations in patients with myelodysplastic syndrome: Incidence and prognostic value

Constantinidou, M., Chalevelakis, G., Economopoulos, T., Koffa, M. D., Liloglou, T., Anastasiou, C. A., Yalouris, A., Spandidos, D. A., & Raptis, S. A. (1995) · National Hellenic Research Foundation Helios Repository (National Hellenic Research Foundation) · Cited by 4 · see citing works

Lessons from the Cancer Genome

Garraway, L. A., & Lander, E. S. (2013) · Cell · doi:10.1016/j.cell.2013.03.002 · Cited by 1,322 · see citing works

Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis.

Cabezas-Wallscheid, N., Klimmeck, D., Hansson, J., Lipka, D., Reyes, A., Wang, Q., Weichenhan, D., Lier, A., von Paleske, L., Renders, S., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.07.005 · Cited by 352 · see citing works

The spliceosome as a target of novel antitumour drugs

Bonnal, S., Vigevani, L., & Valcárcel, J. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3823 · Cited by 403 · see citing works

The neurogenetics of alternative splicing

Vuong, C. K., Black, D. L., & Zheng, S. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.27 · Cited by 340 · see citing works

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes

Gerstung, M., Pellagatti, A., Malcovati, L., Giagounidis, A. A. N., Porta, M. G. D., Jädersten, M., Dolatshad, H., Verma, A. K., Cross, N. C. P., Vyas, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms6901 · Cited by 238 · see citing works

Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome

Kennedy, J. A., & Ebert, B. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0806 · Cited by 170 · see citing works

Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells

Kotini, A. G., Chang, C.-J., Boussaad, I., Delrow, J. J., Dolezal, E. K., Nagulapally, A. B., Perna, F., Fishbein, G. A., Klimek, V. M., Hawkins, R. D., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3178 · Cited by 171 · see citing works

Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway

Chen, S., Wang, Q., Yu, H., Capitano, M. L., Vemula, S., Nabinger, S. C., Gao, R., Yao, C., Kobayashi, M., Geng, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13542-2 · Cited by 121 · see citing works

Clinical and genetic predictors of prognosis in myelodysplastic syndromes

Bejar, R. L. (2014) · Haematologica · doi:10.3324/haematol.2013.085217 · Cited by 102 · see citing works

Gene expression and risk of leukemic transformation in myelodysplasia

Shiozawa, Y., Malcovati, L., Gallì, A., Pellagatti, A., Karimi, M., Sato‐Otsubo, A., Sato, Y., Suzuki, H., Yoshizato, T., Yoshida, K., et al. (2017) · Blood · doi:10.1182/blood-2017-05-783050 · Cited by 81 · see citing works

Clonal hematopoiesis and non-hematologic disorders

Jaiswal, S. (2020) · Blood · doi:10.1182/blood.2019000989 · Cited by 182 · see citing works

Bone marrow–confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia

Mei, Y., Ren, K.-H., Liu, Y.-J., Ma, A., Xia, Z., Han, X., Li, E., Tariq, H., Bao, H., Xie, X., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152673 · Cited by 44 · see citing works

The Y in and Y ang of micro RNA s: leukemia and immunity

So, A. Y., Zhao, J. L., & Baltimore, D. (2013) · Immunological Reviews · doi:10.1111/imr.12043 · Cited by 57 · see citing works

Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS

Keerthivasan, G., Mei, Y., Zhao, B., Zhang, L., Harris, C. E., Gao, J., Basiorka, A. A., Schipma, M. J., McElherne, J., Yang, J. C., et al. (2014) · Blood · doi:10.1182/blood-2014-01-552463 · Cited by 55 · see citing works

The biology and clinical impact of genetic lesions in myeloid malignancies

Lindsley, R. C., & Ebert, B. L. (2013) · Blood · doi:10.1182/blood-2013-06-460295 · Cited by 50 · see citing works

The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes

Zhang, L., Padron, E., & Lancet, J. E. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.10.006 · Cited by 47 · see citing works

Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview.

Zahid, M. F., Malik, U. A., Sohail, M., Hassan, I. N., Ali, S., & Shaukat, M. H. S. (2017) · PubMed Central · Cited by 43 · see citing works

Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?

Bejar, R. L. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0270-5 · Cited by 39 · see citing works

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes

Boultwood, J., Dolatshad, H., Varanasi, S. S., Yip, B. H., & Pellagatti, A. (2013) · Advances in Biological Regulation · doi:10.1016/j.jbior.2013.09.005 · Cited by 36 · see citing works

Prognostic models in myelodysplastic syndromes

Bejar, R. L. (2013) · Hematology · doi:10.1182/asheducation-2013.1.504 · Cited by 38 · see citing works

Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview

Jhanwar, S. C. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.11.002 · Cited by 36 · see citing works

Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS

Follo, M. Y., Marmiroli, S., Faenza, I., Fiume, R., Ramazzotti, G., Martelli, A. M., Gobbi, P., McCubrey, J. A., Finelli, C., Manzoli, F. A., et al. (2012) · Advances in Biological Regulation · doi:10.1016/j.jbior.2012.09.009 · Cited by 35 · see citing works

Modeling Cancer with Pluripotent Stem Cells

Gingold, J., Zhou, R., Lemischka, I., & Lee, D.-F. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.07.007 · Cited by 36 · see citing works

Chromatin condensation during terminal erythropoiesis

Zhao, B., Yang, J. C., & Ji, P. (2016) · Nucleus · doi:10.1080/19491034.2016.1226717 · Cited by 33 · see citing works

Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53

Chen, S., Gao, R., Yao, C., Kobayashi, M., Liu, S. Z., Yöder, M. C., Broxmeyer, H. E., Kapur, R., Boswell, H. S., Mayo, L. D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.325 · Cited by 32 · see citing works

Disruption of erythroid nuclear opening and histone release in myelodysplastic syndromes

Zhao, B., Liu, H., Mei, Y., Liu, Y., Han, X., Yang, J. C., Wickrema, A., & Ji, P. (2019) · Cancer Medicine · doi:10.1002/cam4.1969 · Cited by 29 · see citing works

p53 involvement in clonal hematopoiesis of indeterminate potential

Chen, S., & Liu, Y. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000509 · Cited by 24 · see citing works

Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy

Zahid, M. F., Patnaik, M. M., Gangat, N., Hashmi, S. K., & Rizzieri, D. A. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12771 · Cited by 23 · see citing works

A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia

Goyal, H., Chachoua, I., Pecquet, C., Vainchenker, W., & Constantinescu, S. N. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100712 · Cited by 23 · see citing works

MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways

Youn, M., Huang, H., Cheng, C., Kam, S., Wilkes, M. C., Chae, H.-D., Sridhar, K. J., Greenberg, P. L., Glader, B. E., Narla, A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000537 · Cited by 21 · see citing works

Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia

Martín‐Izquierdo, M., Abáigar, M., Hernández-Sánchez, J. M., Tamborero, D., Cadenas, F. L., Ramos, F., Lumbreras, E., Madinaveitia-Ochoa, A., Megido, M., Labrador, J., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.248807 · Cited by 22 · see citing works

Stress-induced hematopoietic failure in the absence of immediate early response gene X-1 (IEX-1, IER3)

Ramsey, H. E., Zhang, Q., Brown, D. E., Steensma, D. P., Lin, C. P., & Wu, M. X. (2013) · Haematologica · doi:10.3324/haematol.2013.092452 · Cited by 20 · see citing works

Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease

Veiga, C. B., Lawrence, E., Murphy, A. J., Herold, M. J., & Dragoljevic, D. (2021) · Cancers · doi:10.3390/cancers13081968 · Cited by 19 · see citing works

MicroRNA‑145 promotes the apoptosis of leukemic�stem�cells and enhances drug‑resistant K562/ADM cell�sensitivity to adriamycin via the regulation of ABCE1

Wuxiao, Z., Wang, H., Su, Q.-H., Zhou, H., Hu, M. S., Tao, S., Xu, L., Chen, Y., & Hao, X. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4675 · Cited by 17 · see citing works

Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study

Zhang, T., Auer, P. L., Dong, J., Cutler, C. S., Dezern, A. E., Gadalla, S. M., Deeg, H. J., Nazha, A., Carlson, K.-S., Spellman, S. R., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01431-7 · Cited by 16 · see citing works

New Strategies in Myelodysplastic Syndromes: Application of Molecular Diagnostics to Clinical Practice

Tóthová, Z., Steensma, D. P., & Ebert, B. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1251 · Cited by 16 · see citing works

Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.

Brunner, A. M., & Steensma, D. P. (2018) · PubMed · Cited by 15 · see citing works

Myelodysplastic Syndromes: Recent Advancements in Risk Stratification and Unmet Therapeutic Challenges

Bejar, R. L., Tiu, R. V., Sekeres, M. A., & Komrokji, R. S. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e256 · Cited by 14 · see citing works

Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age

Xie, Z., Chen, E. C., Stahl, M. F., & Zeidan, A. M. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101033 · Cited by 13 · see citing works

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)

Brunner, A. M., Gavralidis, A., Ali, N. E. A., Hunter, A. M., Komrokji, R. S., Zeidan, A. M., & Sallman, D. A. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00748-9 · Cited by 13 · see citing works

Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification

Lee, W., Lin, C., Tsai, C., Tien, F., Lo, M., Ni, S., Yao, M., Tseng, M., Kuo, Y., Liu, M.-C., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26799 · Cited by 13 · see citing works

Loss of mDia1 causes neutropenia via attenuated CD11b endocytosis and increased neutrophil adhesion to the endothelium

Mei, Y., Feng, G., Rahimi, N., Zhao, B., Zhang, J., Cao, L., Yang, J. C., Gao, J., Chen, Y., Sumagin, R., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007906 · Cited by 13 · see citing works

Cancer in a dish: progress using stem cells as a platform for cancer research.

Liu, M., Tu, J., Gingold, J. A., Kong, C. S. L., & Lee, D. (2018) · Europe PMC (PubMed Central) · Cited by 13 · see citing works

Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis

Kunze, K., Gamerdinger, U., Leßig, J., Sorokina, M., Brobeil, A., Tur, M. K., Blau, W., Burchardt, A. C., Käbisch, A., Schliesser, G., et al. (2014) · Pathology - Research and Practice · doi:10.1016/j.prp.2014.02.006 · Cited by 12 · see citing works

Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion

Stalmann, U. S. A., Ticconi, F., Snoeren, I., Li, R.-H., Gleitz, H. F. E., Cowley, G., McConkey, M., Wong, A., Schmitz, S., Fuchs, S. N. R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006061 · Cited by 10 · see citing works

Enhancing mitochondrial function in vivo rescues MDS-like anemia induced by pRb deficiency

Sen, T., Jain, M. V., Gram, M., Mattebo, A., Soneji, S., Walkley, C. R., & Singbrant, S. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.06.006 · Cited by 12 · see citing works

Role of p53 in regulation of hematopoiesis in health and disease

Barajas, S., Cai, W., & Liu, Y. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000715 · Cited by 12 · see citing works

H2AX deficiency is associated with erythroid dysplasia and compromised haematopoietic stem cell function

Zhao, B., Tan, T. L., Mei, Y., Yang, J. C., Yu, Y., Verma, A., Liang, Y., Gao, J., & Ji, P. (2016) · Scientific Reports · doi:10.1038/srep19589 · Cited by 12 · see citing works

Clinical and mechanistic insights into the roles of DDX41 in haematological malignancies

Weinreb, J. T., & Bowman, T. V. (2022) · FEBS Letters · doi:10.1002/1873-3468.14487 · Cited by 9 · see citing works

Resveratrol Suppresses Growth and Migration of Myelodysplastic Cells by Inhibiting the Expression of Elevated Cyclin D1 ( CCND1 )

Zhou, W., Xu, S., Yi, Y., Zhou, R., & Chen, X. (2017) · DNA and Cell Biology · doi:10.1089/dna.2017.3846 · Cited by 9 · see citing works

Role of 4‑aminobutyrate aminotransferase (ABAT) and the lncRNA co‑expression network in the development of myelodysplastic syndrome

Chen, Y., Zhao, G., Li, N., Luo, Z., Wang, X., & Gu, J. (2019) · Oncology Reports · doi:10.3892/or.2019.7175 · Cited by 8 · see citing works

From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes

Gadji, M., & Pozzo, A. R. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22689 · Cited by 8 · see citing works

Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance

Song, J., Hussaini, M., Qin, D., Zhang, X., Shao, H., Zhang, L., Gajzer, D. C., Basra, P., Moscinski, L. C., & Zhang, H. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa016 · Cited by 7 · see citing works

Standardizing the Initial Evaluation for Myelodysplastic Syndromes

Marshall, D., & Roboz, G. J. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0180-3 · Cited by 7 · see citing works

The prognostic impact of loss of chromosome 7 material detected by fluorescence in situ hybridization (FISH) in myeloid malignancies

El-Menoufy, M. M., Mourad, Z., & Farahat, N. M. G. (2018) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2018.11.001 · Cited by 6 · see citing works

Gut Microbiota Composition Correlates with Disease Severity in Myelodysplastic Syndrome

Riello, G. B. C., da Silva, P. M., Oliveira, F. A. D. S., de Oliveira, R. T. G., da Silva, F. E. R., França, I. G. D. F., Miyajima, F., Melo, V. M. M., Pinheiro, R. F., & Macêdo, D. S. (2024) · International Journal of Hematology-Oncology and Stem Cell Research · doi:10.18502/ijhoscr.v18i2.15377 · Cited by 4 · see citing works

Adopting solutions for annotation and reporting of next generation sequencing in clinical practice

Song, J., & Hussaini, M. (2020) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2020.e00154 · Cited by 4 · see citing works

Laboratory Test Utilization Management

Reichard, K. K., & Wood, A. J. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2015.10.002 · Cited by 4 · see citing works

The FLT3 internal tandem duplication mutation at disease diagnosis is a negative prognostic factor in myelodysplastic syndrome patients

Sumiyoshi, R., Tashiro, H., Shirasaki, R., Matsuo, T., Yamamoto, T., Matsumoto, K., Ooi, J., & Shirafuji, N. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106790 · Cited by 3 · see citing works

CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS

Bauer, K., Machherndl‐Spandl, S., Kazianka, L., Sadovnik, I., Gültekin, S., Suessner, S., Proell, J., Lauf, J., Hoermann, G., Eisenwort, G., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02015-7 · Cited by 3 · see citing works

Developments in the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes: epidemiology, etiology, genetics, and targeted therapies

Raza, A., Ali, A. M., & Iverson, N. R. (2014) · Advances in Genomics and Genetics · doi:10.2147/agg.s54184 · Cited by 3 · see citing works

Frequent Chromatin Rearrangements in Myelodysplastic Syndromes – What Stands Behind?

Pagáčová, E., Falk, M., Falková, I., Lukášová, E., Michalova, K., Oltová, A., Raška, I., & Kozubek, S. (2014) · Folia Biologica · doi:10.14712/fb2014060s10001 · Cited by 3 · see citing works

Targeting age-related inflammation in myelodysplastic syndromes

Mei, Y., & Ji, P. (2018) · Oncotarget · doi:10.18632/oncotarget.26266 · Cited by 3 · see citing works

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies

Mo, S. S., & Dezern, A. E. (2025) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-025-00762-1 · Cited by 2 · see citing works

How can we incorporate molecular data into the IPSS?

Bejar, R. L. (2022) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2022.101410 · Cited by 2 · see citing works

Progress and possibilities for patient-derived iPSCs and genetically engineered stem cells in cancer modeling and targeted therapies

Pang, L. K., Huang, M.-F., Gingold, J. A., Pena, M., Zhao, R., & Lee, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85767-3.00004-9 · Cited by 2 · see citing works

Analysis of VEGF-A/VEGFR1/VEGFR2 gene expression in patients with myelodysplastic syndrome

Kalitin, N. N., Dudina, G. A., Семочкин, С. В., & Karamysheva, A. F. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh201789739-44 · Cited by 2 · see citing works

Myelodysplastic Syndromes and Modalities of Treatment: An Updated Literature Review

Zamora, D. I., Patel, G. S., Grossmann, I., Rodriguez, K., Soni, M., Joshi, P. K., Patel, S. C., Shreya, D., & Sange, I. (2021) · Cureus · doi:10.7759/cureus.20116 · Cited by 2 · see citing works

Neck Swelling and Fever

Shashidhara, S., Koushik, H., & Trivedi, S. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-26280-8_21 · Cited by 1 · see citing works

Principles of Pathomorphological Differential Diagnosis of Myelodysplastic Syndromes

Kovrigina, A. M., Glinkina, S. A., & Baikov, V. V. (2015) · Clinical oncohematology · doi:10.21320/2500-2139-2015-8-1-62-68 · Cited by 1 · see citing works

The Impact of Malignancy on Adaptive Immunity

Levinson, A. I. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405546-9.00048-0 · Cited by 1 · see citing works

CD41 immune staining of micromegakaryocytes improves the diagnosis of myelodysplastic syndrome and differentiation from pancytopenia

Huang, J., Wang, Z., Huang, L., & Zheng, M. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.10.004 · Cited by 1 · see citing works

Clone wars: co-occurrence of IDH2 R140Q and R172K in myelodysplastic syndromes

Rosso, V., Petiti, J., Dragani, M., Andreani, G., Croce, E., Iacono, M. L., Saglio, G. N., Fava, C., & Cilloni, D. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03913-x · Cited by 1 · see citing works

Improvement of therapy-induced myelodysplastic syndrome by infusion of autologous CD34-positive hematopoietic progenitor cells without chemotherapy

Alary, A., Vignon, M., Carapito, R., Halabi, N. M., Willems, L., Green, A. S., Chapuis, N., Heshmati, F., Cuccuini, W., Kaltenbach, S., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1804562 · Cited by 1 · see citing works

Myelodysplastic syndromes

Olney, H. J., & Beau, M. M. L. (2015) · Wiley eBooks · doi:10.1002/9781118795569.ch7 · Cited by 1 · see citing works

Hematology in Clinical Pathology

Torres, R., Tormey, C. A., & Smith, B. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.06305-x

Chromosomal Aberrations in Cancer

Weele, D. J. V., McNerney, M. E., & Beau, M. M. L. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm008

The Role of mDia1 in the Aberrant Innate Immune Signaling in del(5q) Myelodysplastic Syndromes

Ji, P. (2016)

Myelodysplastic syndromes etiology and pathophysiology

Schroeder, T. A. (2014) · doi:10.2217/fmeb2013.13.53

Mutant P53 in pre-leukemic hematopoietic stem cells and the pathogenesis of Myelodysplastic Syndrome

Chen, S. (2018) · IUScholarWorks (Indiana University) · doi:10.7912/c2mw81

Impacto de las mutaciones somáticas en pacientes con síndromes mielodisplásticos sometidos a distintas modalidades de tratamiento

Berrocal, J. C. C. (2020) · doi:10.14201/gredos.145324

Progress Report: CEq Emergence Assistant (the tool support for the CEq formal method)

Senachak, J. (2008) · Institutional Repositories DataBase (IRDB)

Myelodysplastic Syndromes

Nelkin, H. D., Edwards, A. K., & Watson, M. L. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.mds_overview

Comparative Characteristics of Cytogenetic Abnormalities in Different Types of Myelodysplastic Syndromes

Andreieva, S. V., Korets, K. V., Skorokhod, I. M., & Starodub, H. S. (2022) · Cytology and Genetics · doi:10.3103/s0095452722050024

Evaluación de los índices y la morfología plaquetaria como posibles biomarcadores de valor pronóstico en síndrome mielodisplásico

Berdugo, S. A. C. (2022) · doi:10.11144/javeriana.10554.60981

Predicting leukemic transformation in myelodysplastic syndrome using a transcriptomic signature

Guo, C., Gao, Y.-Y., & Li, Z. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1235315

Myelodysplastic Syndrome: Raeb-1 in a 58-Year-Old Male: A Case Report from Andhra Pradesh, IndiaPreprint

Yanamadala, P. K., Tamanam, R. S., Gannamaneni, A. C., Konkimalla, S. K., Taviti, R. K., & Nadendla, R. R. (2025) · Research Square · doi:10.21203/rs.3.rs-7618308/v1

Additional file 1 of Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study

Zhang, T., Auer, P. L., Dong, J., Cutler, C. S., Dezern, A. E., Gadalla, S. M., Deeg, H. J., Nazha, A., Carlson, K.-S., Spellman, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623103

Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes

Bejar, R. L., Levine, R. L., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 303 · see citing works

The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes

Zhang, L., Padron, E., & Lancet, J. E. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.10.006 · Cited by 47 · see citing works

The genetic and molecular pathogenesis of myelodysplastic syndromes

Shallis, R. M., Ahmad, R., & Zeidan, A. M. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13092 · Cited by 74 · see citing works

Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes

Kulasekararaj, A. G., Mohamedali, A. M., & Mufti, G. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12435 · Cited by 45 · see citing works

Interpreting new molecular genetics in myelodysplastic syndromes

Abdel-Wahab, O. I., & Figueroa, M. E. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.56.3798194 · Cited by 33 · see citing works